Engagement
Translational Evidence Sprint
A four-to-six-week engagement for an early oncology team deciding which evidence to fund before its next development review.

Project fit
When to use a sprint
- Program stage
- Biomarker-dependent solid tumor programs, from preclinical development through early Phase Ib.
- Decision owner
- A scientific, medical or development lead with a defined choice, a review date and access to the relevant evidence.
- Starting materials
- An asset summary, available study reports, known limitations and the options under consideration. The team agrees the scope before sharing confidential materials.
Deliverables
What your team receives
- Decision brief
- A short recommendation for the program review, including alternatives, material uncertainties and the conditions that would change the recommendation.
- Evidence map
- A source-linked record of the observations behind each claim, with the model, population and limitations kept in view.
- Study priorities
- A comparison of evidence options by the question each answers, its dependencies and the development choice it could change.
Working together
From scoping to readout
Scope
Agree the decision, its owner, the options and the review date.
Review
Trace the key claims to their sources and compare the studies that could resolve the uncertainty.
Readout
Review the recommendation with the sponsor and record the conditions for revisiting it.